Impact of SARS-CoV-2 variants on modulating COVID-19 case and death curves in Brazil
DOI:
https://doi.org/10.53660/PRW-1838-3502Resumo
Even though it shares a high genetic similarity to its predecessor, SARS-CoV-2 is more easily transmitted, mainly through aerosols, contact with infected individuals, and contaminated surfaces. Coronaviruses show a high rate of mutations per infectious unit produced, resulting in the emergence of different variants and lineages, potentially having a much greater severity than the original strain. The present study observed an increase in the average number of cases between 2020 and 2021, followed by a reduction in cases in 2022 compared to 2021, which may have been caused by the increase in the vaccination rate between 2021 and 2022. There was a strong anti-vaccine movement, affecting the population's vaccination schedule and interfering in the association between cases, deaths, and vaccine doses, stimulating the selection of strains capable of reducing the effectiveness of the vaccines distributed. There are limitations regarding underreporting, however, it can be concluded that the vaccination schedule stipulated by the Ministry of Health of Brazil effectively controlled the pandemic in Brazil, while the variants are directly related to the modulation of the disease curves.
Downloads
Referências
ANVISA. Coronavírus. 2021. Disponível em: < https://www.gov.br/anvisa/pt-br/acessoainformacao/perguntasfrequentes/paf/coronavirus>. Acesso em: 06 out. 2022.
ANVISA. Vacinas - COVID-19. 2023. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/paf/coronavirus/vacinas. Acesso em: 18 mai. 2023.
CHAKRABORTY, C.; et al. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity. Reviews in Medical Virology, p. e2270, 2021.
CHEN, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, v. 130, n. 5, p. 2620–2629, 2020.
CHEN, J. et al. Mutations strengthened SARS-CoV-2 infectivity. Journal of molecular biology, v. 432, n. 19, p. 5212-5226, 2020.
CNN BRASIL, Brasil registra 1º caso da variante XBB.1.5 do coronavírus; saiba como prevenir. 2023. Disponível em: https://www.cnnbrasil.com.br/saude/brasil-registra-1o-caso-da-variante-xbb-1-5-do-coronavirus-saiba-como-prevenir/. Acesso em: 08 jan. 2023.
COLLIE, S. et al. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. New England Journal of Medicine, 2021.
CORONAVÍRUS BRASIL. COVID-19: PAINEL CORONAVÍRUS, 2023. Disponível em: https://covid.saude.gov.br/. Acesso em: 17 mai. 2023.
DUONG, D. Alpha, Beta, Delta, Gamma: What’s important to know about SARS-CoV-2 variants of concern?. Canadian medical association journal, v. 193, n. 27, p. E1059-E1060, 2021.
FRIAS, D.F.R. et al. Efeitos da vacinação contra COVID-19 com relação a evolução dos casos no estado de Mato Grosso do Sul. Revista Cereus, v. 13, n. 4, p. 149-157, 2021.
G1. Covid: variante Éris é confirmada pela 1ª vez no Brasil. 2023. Disponível em: https://g1.globo.com/saude/coronavirus/noticia/2023/08/18/covid-variante-eris-e-confirmada-pela-1a-vez-no-brasil.ghtml. Acesso em 21 ago. 2023.
KANTOR, I. N. Las variantes de SARS-CoV-2 y la llamada resistencia a las vacunas. Medicina (Buenos Aires), v. 81, n. 3, p. 421-426, 2021.
KONINGS, F. et al. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nature microbiology, v. 6, n. 7, p. 821-823, 2021.
KORBER, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell, v. 182, n. 4, p. 812-827. e19, 2020.
LAMERS, M. M.; HAAGMANS, B. L. SARS-CoV-2 pathogenesis. Nature Reviews Microbiology, v. 20, n. 5, p. 270-284, 2022.
LU, H. et al. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. Journal of medical virology, v. 92, n. 4, p. 401, 2020.
MICHELON, C.M. Principais variantes do SARS-CoV-2 notificadas no Brasil. Revista Brasileira de Análises Clínicas, v. 53, n. 2, p. 109-116, 2021.
MINISTÉRIO DA SAÚDE. Programa Nacional de Imunizações - PNI, 2023b. Disponível em: https://www.gov.br/saude/pt-br/coronavirus/vacinas/pni. Acesso em: 18 mai. 2023.
MINISTÉRIO DA SAÚDE. Vacinação Covid-19 reforço. 2023a. Disponível em: https://www.gov.br/saude/pt-br/campanhas-da-saude/2022/vacinacao-covid-19-reforco-2022. Acesso em: 18 mai. 2023.
OLIVEIRA, S.S. A vacinação contra Covid-19 no Brasil, estratégias e desafios na atenção primária: revisão integrativa. Trabalho de Conclusão de Curso (Bacharelado em Enfermagem), Escola de Ciências Sociais e da Saúde, Pontifícia Universidade Católica de Goiás, 42p, 2022.
OMS. TAG-VE statement on Omicron sublineages BQ.1 and XBB. 2022. Disponível em: https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb. Acesso em: 08 jan. 2023.
OPAS/WHO. Coronavirus disease (COVID-19): Vaccines, 2022. Disponível em: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines. Acesso em: 6 out. 2022.
OPAS/WHO. Histórico da pandemia de COVID-19. 2020. Disponível em: https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19. Acesso em: 6 out. 2022.
OUR WORLD IN DATA. Coronavirus Pandemic (COVID-19). Disponível em: https://ourworldindata.org/coronavirus. Acesso em: 11 out. 2022.
REDE GENÔMICA FIOCRUZ. Vigilância genômica do SARS-CoV-2 no Brasil: Genomas depositados no GISAID, 2022. Disponível em: http://www.genomahcov.fiocruz.br/grafico/. Acesso em: 28 jan. 2023.
SARINHO, F. W. et al. Vacinas COVID-19 e imunobiológicos. Arq Asma Alerg Imunol, v. 5, n.2, 2021.
SENDER, R. et al. The total number and mass of SARS-CoV-2 virions. Proceedings of the National Academy of Sciences, v. 118, n. 25, p. e2024815118, 2021.
SHIMIZU, H. E. et al. Regionalização e crise federativa no contexto da pandemia da Covid-19: impasses e perspectivas. Saúde em Debate, v. 45, p. 945-957, 2021.
STOWE, J. et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Public Health England, 2021. Disponível em: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf. Acesso em: 18 mai. 2023.
VASILEIOU, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet, v. 397, n. 10285, p. 1646-1657, 2021.
WHO. Tracking SARS-CoV-2 Variants. 2022. Disponível em: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Acesso em: 06 Out. 2022.
YESUDHAS, D. et al. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection, v. 49, n. 2, p. 199-213, 2021.
